T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer

SIMPLE SUMMARY: Real-world data studies suggest trastuzumab emtansine (T-DM1) may be less effective following pertuzumab treatment in patients with metastatic breast cancer. However, the short time frame between pertuzumab and T-DM1 approvals may have biased these studies toward selecting pertuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanglier, Thibaut, Fabi, Alessandra, Flores, Carlos, Flahavan, Evelyn M., Pena-Murillo, Claudia, Meyer, Anne-Marie, Montemurro, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139620/
https://www.ncbi.nlm.nih.gov/pubmed/35626072
http://dx.doi.org/10.3390/cancers14102468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139620/
https://www.ncbi.nlm.nih.gov/pubmed/35626072
http://dx.doi.org/10.3390/cancers14102468

Ejemplares similares